Discover open access scientific publications

Search, annotate, share and cite publications

Publications by E. Normant

The Novel Bispecific Cd47-Cd19 Antibody Tg-1801 Potentiates the Activity of Ublituximab-Umbralisib (U2) Drug Combination in Preclinical Models of B-NHL

Hematological Oncology

English

Purification, cDNA Cloning, Functional Expression, and Characterization of a 26-kDa Endogenous Mammalian Carboxypeptidase Inhibitor.

Proceedings of the National Academy of Sciences of the United States of America

Multidisciplinary

1995

English

Related publications

Phase I/Ii Study of Umbralisib (Tgr-1202) in Combination With Ublituximab (Tg-1101) and Pembrolizumab in Patients With Rel/Ref CLL and Richter's Transformation

Hematological Oncology

English

Anti-Cd47 Agent Boosts Macrophage Activity in NHL

Cancer Discovery

Oncology

2018

English

Tolerability and Activity of Chemo-Free Triplet Combination of TGR-1202, Ublituximab, and Ibrutinib in Patients With Advanced CLL and NHL.

Journal of Clinical Oncology

English

Synergistic Antitumor Effect of Bispecific CD19 X CD3 and CD19 X CD16 Diabodies in a Preclinical Model of Non-Hodgkin's Lymphoma

Journal of Immunology

Allergy

Immunology

2002

English

Targeting a Membrane-Proximal Epitope on Mesothelin Increases the Tumoricidal Activity of a Bispecific Antibody Blocking CD47 on Mesothelin-Positive Tumors

English

Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination With Vorinostat in KRAS-Mutant Colorectal Cancer Models

Clinical Cancer Research

Cancer Research

Oncology

2011

English

Clinical Activity of Regn1979, an Anti-Cd20 X Anti-Cd3 Bispecific Antibody (Ab) in Patients (Pts) With (W/) Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-Nhl)

Hematological Oncology

English

Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates

Pharmaceutical Research

Pharmaceutical Science

2014

English

Curaxin CBL0137 Eradicates Drug Resistant Cancer Stem Cells and Potentiates Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer

Oncotarget

Oncology

2014

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by E. Normant

The Novel Bispecific Cd47-Cd19 Antibody Tg-1801 Potentiates the Activity of Ublituximab-Umbralisib (U2) Drug Combination in Preclinical Models of B-NHL

Purification, cDNA Cloning, Functional Expression, and Characterization of a 26-kDa Endogenous Mammalian Carboxypeptidase Inhibitor.

Related publications

Phase I/Ii Study of Umbralisib (Tgr-1202) in Combination With Ublituximab (Tg-1101) and Pembrolizumab in Patients With Rel/Ref CLL and Richter's Transformation

Anti-Cd47 Agent Boosts Macrophage Activity in NHL

Tolerability and Activity of Chemo-Free Triplet Combination of TGR-1202, Ublituximab, and Ibrutinib in Patients With Advanced CLL and NHL.

Synergistic Antitumor Effect of Bispecific CD19 X CD3 and CD19 X CD16 Diabodies in a Preclinical Model of Non-Hodgkin's Lymphoma

Targeting a Membrane-Proximal Epitope on Mesothelin Increases the Tumoricidal Activity of a Bispecific Antibody Blocking CD47 on Mesothelin-Positive Tumors

Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination With Vorinostat in KRAS-Mutant Colorectal Cancer Models

Clinical Activity of Regn1979, an Anti-Cd20 X Anti-Cd3 Bispecific Antibody (Ab) in Patients (Pts) With (W/) Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-Nhl)

Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates

Curaxin CBL0137 Eradicates Drug Resistant Cancer Stem Cells and Potentiates Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer